TAR-200 is an investigational device that delivers gemcitabine chemotherapy directly into the bladder for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer. The pretzel-shaped system is inserted via catheter and releases the drug over three weeks per cycle. It can be used alone or with cetrelimab, a PD-1 inhibitor, for patients who cannot or refuse to undergo bladder removal surgery.
Recent Phase 2b trial results (SunRISe-1) showed high efficacy and good tolerability. Patients with carcinoma in situ achieved an 82.4% complete response rate, and those with papillary-only disease had an 85.3% six-month disease-free survival rate. Median duration of response for CIS patients was 25.8 months, and many remained cancer-free at one year.
TAR-200 provides a bladder-sparing alternative to surgery, with mostly low-grade urinary side effects and few severe adverse events. These findings suggest it could become a leading therapy for patients with limited treatment options.